


PHARMACEUTICAL 2023

CATALYST PHARMACEUTICALS INC. Rank 30 of 446









PHARMACEUTICAL 2023



CATALYST PHARMACEUTICALS INC.



Rank 30 of 446

The relative strengths and weaknesses of CATALYST PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CATALYST PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 117% points. The greatest weakness of CATALYST PHARMACEUTICALS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 223% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	320,797
Cost of Goods Sold	34,393
Intangible Assets	32,471
Liabilities, Current	57,588
Liabilities, Non-Current	17,621
Other Assets	21,515
Other Compr. Net Income	172
Other Expenses	21,640
Other Liabilities	0
Other Net Income	2,881
Other Revenues	214,203
Property and Equipment	847
Research and Development	19,789
Selling, General and Administrative Expense	58,183

Output Variable	Value in 1000 USD
Assets	375,630
Liabilities	75,209
Expenses	134,005
Revenues	214,203
Stockholders Equity	300,421
Net Income	83,079
Comprehensive Net Income	83,165
Economic Capital Ratio	266%

